ACTU
Actuate·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ACTU
Actuate Therapeutics, Inc.
A biopharmaceutical company focused on developing clinical stage therapies for cancer treatment
Biological Technology
01/16/2015
08/13/2024
NASDAQ Stock Exchange
10
12-31
Common stock
1751 River Run, Suite 400 Fort Worth, Texas 76107
--
Actuate Therapeutics, Inc., was incorporated in Delaware on January 16, 2015 as Apotheca Therapeutics, Inc., and changed its name to Actuate Therapeutics, Inc., on October 1, 2015. The company is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers by inhibiting glycogen synthase kinase 3 (GSK-3). They are developing elraglusib (formerly 9-ING-41), a small molecule designed to enter cancer cells and block the function of the GSK-3β enzyme, a major regulator of complex biological signaling cascades, including oncogene-mediated signaling cascades that lead to tumor cell survival, growth, migration and invasion.
Company Financials
EPS
ACTU has released its 2025 Q2 earnings. EPS was reported at -0.3, versus the expected -0.31, beating expectations. The chart below visualizes how ACTU has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
